"目錄號(hào): HY-15263
Cell Cycle/DNA DamageMetabolic Enzyme/Protease-
Retaspimycin(IPI 504)是HSP90抑制劑，具有抗增殖和抗腫瘤活性弹惦。
相關(guān)產(chǎn)品
17-AAG-Triptolide-NVP-AUY922-Ganetespib-Geldanamycin-Teprenone-Rocaglamide-VER-155008-AT13387-Retaspimycin Hydrochloride-Alvespimycin hydrochloride-Debio 0932-BIIB021-PU-H71-NVP-HSP990-
生物活性
Description
Retaspimycin(IPI 504) is a small-molecule inhibitor of heat shock protein 90 (HSP90) with antiproliferative and antineoplastic activities. IC50 Value:Target: HSPRetaspimycin binds to and inhibits the cytosolic chaperone functions of HSP90, which maintains the stability and functional shape of many oncogenic signaling proteins and may be overexpressed or overactive in tumor cells. Retaspimycin-mediated inhibition of HSP90 promotes the proteasomal degradation of oncogenic signaling proteins in susceptible tumor cell populations, which may result in the induction of apoptosis.
Clinical Trial
Infinity Pharmaceuticals, Inc.
Non Small Cell Lung Cancer
May 2011
Phase 2
Infinity Pharmaceuticals, Inc.
Prostate Cancer-Prostatic Neoplasms-Cancer of the Prostate
November 2007
Phase 2
Infinity Pharmaceuticals, Inc.
Solid Tumors
December 2007
Phase 1
Infinity Pharmaceuticals, Inc.
Multiple Myeloma
June 2005
Phase 1
Infinity Pharmaceuticals, Inc.
Breast Cancer-HER2 Positive Breast Cancer-Metastatic Breast Cancer-Cancer of the Breast
March 2009
Phase 2
Infinity Pharmaceuticals, Inc.
Metastatic Melanoma
February 2008
Phase 2
Infinity Pharmaceuticals, Inc.
Gastrointestinal Stromal Tumors-Soft Tissue Sarcomas
December 2005
Phase 1
MedImmune LLC
Breast Cancer
April 2008
Phase 1-Phase 2
Infinity Pharmaceuticals, Inc.
Dedifferentiated Liposarcoma
January 2010
Phase 2
Infinity Pharmaceuticals, Inc.
Non-small Cell Lung Cancer
July 2011
Phase 1-Phase 2
Infinity Pharmaceuticals, Inc.
Lung Cancer
January 2007
Phase 1-Phase 2
Infinity Pharmaceuticals, Inc.-MedImmune LLC-AstraZeneca
Gastrointestinal Stromal Tumors
August 2008
Phase 3
Massachusetts General Hospital-Dana-Farber Cancer Institute-Infinity Pharmaceuticals, Inc.
Lung Cancer-Stage IIIb Lung Cancer-Stage IV Lung Cancer
October 2010
Phase 2
View MoreCollapse
References
